Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Shares Up 12.6%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) shares were up 12.6% on Monday . The company traded as high as $25.76 and last traded at $25.76. Approximately 4,000 shares traded hands during trading, an increase of 433% from the average daily volume of 750 shares. The stock had previously closed at $22.87.

Swedish Orphan Biovitrum AB (publ) Price Performance

The company has a debt-to-equity ratio of 0.34, a current ratio of 0.66 and a quick ratio of 0.46. The company has a fifty day simple moving average of $25.24 and a two-hundred day simple moving average of $24.30.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last posted its earnings results on Thursday, February 8th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.26). Swedish Orphan Biovitrum AB (publ) had a net margin of 9.29% and a return on equity of 8.20%. The company had revenue of $643.39 million during the quarter, compared to analysts’ expectations of $668.74 million.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.